395 related articles for article (PubMed ID: 30782608)
1. FNDC5/Irisin inhibits pathological cardiac hypertrophy.
Yu Q; Kou W; Xu X; Zhou S; Luan P; Xu X; Li H; Zhuang J; Wang J; Zhao Y; Xu Y; Peng W
Clin Sci (Lond); 2019 Mar; 133(5):611-627. PubMed ID: 30782608
[TBL] [Abstract][Full Text] [Related]
2. Irisin alleviates pressure overload-induced cardiac hypertrophy by inducing protective autophagy via mTOR-independent activation of the AMPK-ULK1 pathway.
Li RL; Wu SS; Wu Y; Wang XX; Chen HY; Xin JJ; Li H; Lan J; Xue KY; Li X; Zhuo CL; Cai YY; He JH; Zhang HY; Tang CS; Wang W; Jiang W
J Mol Cell Cardiol; 2018 Aug; 121():242-255. PubMed ID: 30053525
[TBL] [Abstract][Full Text] [Related]
3. FNDC5/Irisin attenuates diabetic cardiomyopathy in a type 2 diabetes mouse model by activation of integrin αV/β5-AKT signaling and reduction of oxidative/nitrosative stress.
Lin C; Guo Y; Xia Y; Li C; Xu X; Qi T; Zhang F; Fan M; Hu G; Zhao H; Zhao H; Liu R; Gao E; Yan W; Tao L
J Mol Cell Cardiol; 2021 Nov; 160():27-41. PubMed ID: 34224725
[TBL] [Abstract][Full Text] [Related]
4. FNDC5 alleviates oxidative stress and cardiomyocyte apoptosis in doxorubicin-induced cardiotoxicity via activating AKT.
Zhang X; Hu C; Kong CY; Song P; Wu HM; Xu SC; Yuan YP; Deng W; Ma ZG; Tang QZ
Cell Death Differ; 2020 Feb; 27(2):540-555. PubMed ID: 31209361
[TBL] [Abstract][Full Text] [Related]
5. Irisin ameliorates high glucose-induced cardiomyocytes injury via AMPK/mTOR signal pathway.
Deng J; Zhang N; Chen F; Yang C; Ning H; Xiao C; Sun K; Liu Y; Yang M; Hu T; Zhang Z; Jiang W
Cell Biol Int; 2020 Nov; 44(11):2315-2325. PubMed ID: 32770767
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol as a new inhibitor of immunoproteasome prevents PTEN degradation and attenuates cardiac hypertrophy after pressure overload.
Chen C; Zou LX; Lin QY; Yan X; Bi HL; Xie X; Wang S; Wang QS; Zhang YL; Li HH
Redox Biol; 2019 Jan; 20():390-401. PubMed ID: 30412827
[TBL] [Abstract][Full Text] [Related]
7. Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy.
Li HL; Yin R; Chen D; Liu D; Wang D; Yang Q; Dong YG
J Cell Biochem; 2007 Apr; 100(5):1086-99. PubMed ID: 17266062
[TBL] [Abstract][Full Text] [Related]
8. Sophoricoside ameliorates cardiac hypertrophy by activating AMPK/mTORC1-mediated autophagy.
Gao M; Hu F; Hu M; Hu Y; Shi H; Zhao GJ; Jian C; Ji YX; Zhang XJ; She ZG; Li H; Zhu L
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 32964914
[TBL] [Abstract][Full Text] [Related]
9. Sodium (±)-5-bromo-2-(α-hydroxypentyl) benzoate ameliorates pressure overload-induced cardiac hypertrophy and dysfunction through inhibiting autophagy.
Wang B; Shen D; Tang J; Li J; Xiao Y; Chen X; Cao C; Han D; Gao E; Zhao W; Zhang J; Chang J
J Cell Mol Med; 2019 Sep; 23(9):6048-6059. PubMed ID: 31222939
[TBL] [Abstract][Full Text] [Related]
10. The alteration of protein prenylation induces cardiomyocyte hypertrophy through Rheb-mTORC1 signalling and leads to chronic heart failure.
Xu N; Guan S; Chen Z; Yu Y; Xie J; Pan FY; Zhao NW; Liu L; Yang ZZ; Gao X; Xu B; Li CJ
J Pathol; 2015 Apr; 235(5):672-85. PubMed ID: 25385233
[TBL] [Abstract][Full Text] [Related]
11. Aldolase promotes the development of cardiac hypertrophy by targeting AMPK signaling.
Li Y; Zhang D; Kong L; Shi H; Tian X; Gao L; Liu Y; Wu L; Du B; Huang Z; Liang C; Wang Z; Yao R; Zhang Y
Exp Cell Res; 2018 Sep; 370(1):78-86. PubMed ID: 29902536
[TBL] [Abstract][Full Text] [Related]
12. KLK11 promotes the activation of mTOR and protein synthesis to facilitate cardiac hypertrophy.
Wang Y; Liao H; Wang Y; Zhou J; Wang F; Xie Y; Zhao K; Gao W
BMC Cardiovasc Disord; 2021 May; 21(1):266. PubMed ID: 34059001
[TBL] [Abstract][Full Text] [Related]
13. Metformin promotes irisin release from murine skeletal muscle independently of AMP-activated protein kinase activation.
Li DJ; Huang F; Lu WJ; Jiang GJ; Deng YP; Shen FM
Acta Physiol (Oxf); 2015 Mar; 213(3):711-21. PubMed ID: 25382002
[TBL] [Abstract][Full Text] [Related]
14. Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response.
Shimano M; Ouchi N; Shibata R; Ohashi K; Pimentel DR; Murohara T; Walsh K
J Mol Cell Cardiol; 2010 Aug; 49(2):210-20. PubMed ID: 20206634
[TBL] [Abstract][Full Text] [Related]
15. Choline ameliorates cardiac hypertrophy by regulating metabolic remodelling and UPRmt through SIRT3-AMPK pathway.
Xu M; Xue RQ; Lu Y; Yong SY; Wu Q; Cui YL; Zuo XT; Yu XJ; Zhao M; Zang WJ
Cardiovasc Res; 2019 Mar; 115(3):530-545. PubMed ID: 30165480
[TBL] [Abstract][Full Text] [Related]
16. Puerarin prevents cardiac hypertrophy induced by pressure overload through activation of autophagy.
Liu B; Wu Z; Li Y; Ou C; Huang Z; Zhang J; Liu P; Luo C; Chen M
Biochem Biophys Res Commun; 2015 Aug; 464(3):908-15. PubMed ID: 26188094
[TBL] [Abstract][Full Text] [Related]
17. Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation.
Zhou Y; He X; Chen Y; Huang Y; Wu L; He J
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):394-9. PubMed ID: 26519882
[TBL] [Abstract][Full Text] [Related]
18. MG53, A Novel Regulator of KChIP2 and I
Liu W; Wang G; Zhang C; Ding W; Cheng W; Luo Y; Wei C; Liu J
Circulation; 2019 Apr; 139(18):2142-2156. PubMed ID: 30760025
[TBL] [Abstract][Full Text] [Related]
19. GPR39 promotes cardiac hypertrophy by regulating the AMPK-mTOR pathway and protein synthesis.
Liao H; Gao W; Ma J; Xue H; Wang Y; Huang D; Yan F; Ye Y
Cell Biol Int; 2021 Jun; 45(6):1211-1219. PubMed ID: 33554444
[TBL] [Abstract][Full Text] [Related]
20. SIRT2 Acts as a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy.
Tang X; Chen XF; Wang NY; Wang XM; Liang ST; Zheng W; Lu YB; Zhao X; Hao DL; Zhang ZQ; Zou MH; Liu DP; Chen HZ
Circulation; 2017 Nov; 136(21):2051-2067. PubMed ID: 28947430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
